Legal Status Overview
Gray AreaNew York has no statute, regulation, or Board of Pharmacy rule naming "peptides" or "research chemicals" as a distinct legal category, so peptide legality in New York, NY is set by the same framework that governs any other drug: New York Education Law Article 137 (the Pharmacy Practice Act, administered by the NYS Education Department/Board of Pharmacy) layered on top of the federal Food, Drug & Cosmetic Act's compounding rules (FDCA Sections 503A and 503B) and FDA drug-approval requirements. A peptide that is an FDA-approved drug (e.g., FDA-approved semaglutide/tirzepatide products) can be lawfully prescribed and dispensed in New York like any prescription medicine, and a non-approved peptide can only be lawfully compounded by a New York-registered 503A pharmacy or 503B outsourcing facility if it appears on FDA's 503A/503B bulks list, is a component of an approved drug, or has a USP/NF monograph. Peptides marketed as "research use only" for human consumption, including BPC-157 and TB-500, have no such approved or monograph status and are therefore treated as unapproved/misbranded drugs under federal law that New York pharmacy law does not separately legalize.
Key Points
- New York has no statute, administrative code section, or Board of Pharmacy rule that names peptides or "research chemicals" as a distinct regulated category, according to a sourced review of New York statutes and pharmacy regulations. [1]
- New York Education Law Article 137 (the state Pharmacy Practice Act) is the general framework that governs who may compound, possess, dispense, or retail drugs in New York, including peptide-based drugs, and it charges the State Board of Pharmacy with regulating and controlling the sale and standards of drugs in the state. [2]
- Under Article 137, any out-of-state pharmacy, manufacturer, or outsourcing facility that ships compounded drugs (including compounded peptides) into New York must register as a nonresident establishment with the New York State Education Department and comply with both home-state and New York requirements. [3]
- Under federal law, which New York's compounding rules incorporate by reference, a peptide may only be legally compounded by a 503A pharmacy if it is the active ingredient of an FDA-approved drug, has a USP/NF monograph, or has been placed on FDA's 503A bulks list after safety review; peptides lacking all three, such as most research-grade BPC-157 or TB-500 products, fall outside that lawful pathway. [6]
- BPC-157 is not included in the FDA's Approved Drugs database and is treated by federal authorities as an unapproved new drug circulating in health-and-wellness products, a federal determination that applies in New York as in every other state because New York has not separately scheduled or exempted it. [7]
- A person cannot lawfully buy or import research-use-only peptides like BPC-157 or TB-500 for personal human use in New York, NY, because no FDA approval, compounding monograph, or New York exemption covers that use; the only lawful route is a valid prescription filled by a New York-licensed or New York-registered pharmacy. (No reliable source found for this point — flagged as unverified rather than stated as fact.)
- New York General Business Law Section 391-oo, effective April 22, 2024 (with enforcement beginning April 22, 2025), bars retail sale of muscle-building or weight-loss dietary supplements, a category that online peptide sellers are often grouped with, to anyone under 18. [8]
- The New York State Office of Professional Medical Conduct (OPMC) actively investigates physicians who prescribe unapproved substances, meaning a New York-licensed prescriber who writes scripts for unapproved research peptides faces state medical-board scrutiny even though the peptide itself is not separately scheduled. [9]
Peptide-by-peptide status in New York
| BPC-157 | BPC-157 has no FDA approval and is not on the federal 503A bulks list in any state including New York, NY, so it is an unapproved research chemical that cannot be lawfully sold, compounded, or prescribed for human use there despite being widely available online. [7] |
|---|---|
| TB-500 (Thymosin Beta-4) | TB-500 is not an FDA-approved drug and is not specifically addressed by any New York statute or Board of Pharmacy rule, placing it in the same unapproved "research use only" gray zone as BPC-157 under the general New York/federal drug framework. [1] |
| Semaglutide / Tirzepatide (GLP-1 class) | FDA-approved brand-name semaglutide and tirzepatide products are legal prescription medicines in New York, NY, but compounded (non-brand) versions may only be dispensed by a New York-registered 503A or 503B pharmacy under the FDA's bulks-list and shortage rules, which narrowed sharply once FDA resolved the national semaglutide and tirzepatide shortages. [4] |
| HGH / Somatropin | Human growth hormone is a federally scheduled prescription drug under the Anabolic Steroids Control Act framework and FDA rules, and in New York, NY it can only be legally dispensed by a licensed pharmacy pursuant to a valid prescription, with no separate New York carve-out making it more freely available. |
Sources
Last researched: 2026-10-02
Frequently asked questions
Can I buy peptides like BPC-157 in New York without a prescription?
No, you cannot lawfully buy BPC-157 or similar unapproved peptides for human use in New York, NY without a prescription, because BPC-157 is not FDA-approved and is not on the federal compounding bulks list, so no New York pharmacy may legally dispense it over the counter. [7]
Is it legal to import peptides into New York for personal use?
There is no New York-specific personal-import exemption for research peptides, so bringing or ordering unapproved peptides like BPC-157 or TB-500 into New York, NY for human use falls outside the lawful federal/state drug-approval and compounding pathway and carries legal risk, even though individual buyers are rarely the direct target of enforcement.
Can a telehealth doctor legally prescribe peptides to someone in New York?
A telehealth provider can prescribe an FDA-approved peptide drug (like approved semaglutide) to a patient in New York, NY, and the New York State Department of Health finalized rules in May 2025 governing prescribing of certain drugs through telemedicine, but prescribing an unapproved research peptide does not become lawful simply because it is done via telehealth. [10]
What happens if a compounding pharmacy in New York sells unapproved peptides like BPC-157?
A New York compounding pharmacy that compounds or sells a peptide not on the FDA's 503A/503B bulks list, such as BPC-157, risks FDA enforcement as an unapproved/misbranded drug and New York Education Department/Board of Pharmacy discipline for operating outside Article 137's registration and compounding rules. [2]
Are compounded semaglutide or tirzepatide peptides still available in New York?
Compounded semaglutide and tirzepatide are much harder to obtain lawfully in New York, NY than during the 2023-2024 shortage period, because FDA's resolution of the national GLP-1 shortages removed the main legal basis 503A/503B pharmacies had for mass-compounding copies of the approved drugs. [6]